Alzheimer's disease: current and future therapeutic perspectives

Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):73-89. doi: 10.1016/s0278-5846(00)00149-4.


1. A better understanding of the pathophysiology of AD has been made possible through population-based epidemiological studies, human genetic and post-mortem studies, leading to a number of testable hypothesis towards delaying progression. 2. A number of disease milestones have been identified as therapeutic targets, such as conversion from MCI to diagnosable dementia. 3. Clinicians caring for patients with AD have currently available a number of symptomatic drugs, and will have in the future the ability to predict the risk for asymptomatic individuals to develop AD, and provide advice towards prevention.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / physiopathology*
  • Alzheimer Disease / psychology
  • Cholinergic Agents / pharmacology
  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / therapeutic use*
  • Clinical Trials as Topic
  • Cognition
  • Disease Progression
  • Humans


  • Cholinergic Agents
  • Cholinesterase Inhibitors